IL6R and metastatic neoplasm: We also classified the patient subset with non-metastatic disease into three groups based on their IL33Rα/IL1RA levels: (i) both with levels above the corresponding median; (ii) only one of the mediators having a level above the median; and (iii) both levels below the corresponding median.